EGFR / c-met bispecific antibodies and uses thereof
CN122161850APending Publication Date: 2026-06-05ABIOTECH PHARMACEUTICAL CO LTD
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- ABIOTECH PHARMACEUTICAL CO LTD
- Filing Date
- 2024-07-22
- Publication Date
- 2026-06-05
AI Technical Summary
Technical Problem
The existing EGFR/c-Met bispecific antibodies have insufficient safety and are limited in their therapeutic effects on TKI-resistant cancers.
Method used
A bispecific antibody molecule with the desired dual-target selection specificity, anti-tumor efficacy and safety prospects was developed to antagonize the binding of ligands by specifically binding to EGFR and c-Met. Inhibit the phosphorylation and internalization of target proteins and enhance ADCC activity.
Benefits of technology
Effective treatment of TKI-resistant cancers has been achieved, which significantly inhibits the proliferation of tumor cells, has high safety and production advantages, and is suitable for the treatment of patients with osimertinib-resistant tumors.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122161850A_ABST
Abstract
Bispecific antibody against EGFR and c-Met. The heterodimeric interaction between the EGFR binding arm and the c-Met binding arm of the bispecific antibody is stronger than the interaction of each in the source homodimer by modifying the Fc segment amino acid sequence of the binding arm, so that it can be assembled into a heterodimer in vitro; its effect on inhibiting the proliferation of EGFR and c-Met double-positive tumor cells is stronger than the combination of EGFR monoclonal antibody and c-Met monoclonal antibody, mediates antibody-dependent cellular cytotoxicity (ADCC), promotes target protein internalization and inhibits the proliferation of osimertinib acquired resistant cell lines. Since the prepared bispecific antibody is simple to prepare, stable in structure, and can obtain a pure bispecific antibody by in vitro assembly, it is expected to better meet the clinical treatment needs, and therefore has a good market prospect.
Need to check novelty before this filing date? Find Prior Art